Atossa Therapeutics宣布授予美国专利

2025-04-22 20:52

Atossa Therapeutics (NASDAQ:ATOS) has announced that the U. S. Patent and Trademark Office has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.
This newly granted patent further fortifies Atossa’s intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, encompassing novel compositions and methods related to (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator.
Specifically, the patent covers enteric oral formulations of (Z)-endoxifen and salts thereof, as well as their use in treating hormone-dependent breast and reproductive tract disorders.
"This patent not only reinforces our commitment to protecting our intellectual property but also underscores our dedication to delivering effective therapeutic options to patients," said Steven Quay, M.D., Ph.D., Atossa’s President and CEO.

More on Atossa Therapeutics